Hong Kong Stock Movement | INSILICO (03696) Surges Nearly 15% in Morning Session, Completes First Dosing in Phase IIa Trial for IBD Candidate Drug

Stock News01-12

INSILICO (03696) rose nearly 15% in morning trading, hitting a high of HK$54, representing an increase of over 124% from its IPO price of HK$24.05. As of writing, the stock was up 14.89% at HK$54, with a turnover of HK$92.17 million.

The company announced that it has completed the first subject dosing in a Phase IIa clinical trial named BETHESDA for its innovative PHD inhibitor, ISM5411. This novel candidate drug, which was developed with the assistance of the group's proprietary generative AI platform Pharma.AI, is a gut-restricted therapy intended for the treatment of Inflammatory Bowel Disease (IBD), and its generic name, Garutadustat, was recently officially approved by the United States Adopted Names (USAN) Council.

Notably, on January 5, INSILICO announced that it had entered into a multi-year anti-cancer drug research collaboration with Servier. According to the announcement, the total potential value of the collaboration is $888 million. INSILICO is eligible to receive up to $32 million in an upfront payment and near-term research and development milestone payments. INSILICO will utilize its self-developed AI platform, Pharma.AI, to focus on challenging targets in the oncology field to identify and develop novel therapeutic agents. Servier will share the R&D costs and lead the subsequent clinical validation and commercialization process.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1170354154?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 10:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170354154","market":"nz","top_or_hot":-1,"title":"Hong Kong Stock Movement | INSILICO (03696) Surges Nearly 15% in Morning Session, Completes First Dosing in Phase IIa Trial for IBD Candidate Drug","media":"Stock News","content":"<p>INSILICO (03696) rose nearly 15% in morning trading, hitting a high of HK$54, representing an increase of over 124% from its IPO price of HK$24.05. As of writing, the stock was up 14.89% at HK$54, with a turnover of HK$92.17 million.</p>\n<p>The company announced that it has completed the first subject dosing in a Phase IIa clinical trial named BETHESDA for its innovative PHD inhibitor, ISM5411. This novel candidate drug, which was developed with the assistance of the group's proprietary generative AI platform Pharma.AI, is a gut-restricted therapy intended for the treatment of Inflammatory Bowel Disease (IBD), and its generic name, Garutadustat, was recently officially approved by the United States Adopted Names (USAN) Council.</p>\n<p>Notably, on January 5, INSILICO announced that it had entered into a multi-year anti-cancer drug research collaboration with Servier. According to the announcement, the total potential value of the collaboration is $888 million. INSILICO is eligible to receive up to $32 million in an upfront payment and near-term research and development milestone payments. INSILICO will utilize its self-developed AI platform, Pharma.AI, to focus on challenging targets in the oncology field to identify and develop novel therapeutic agents. Servier will share the R&D costs and lead the subsequent clinical validation and commercialization process.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Movement | INSILICO (03696) Surges Nearly 15% in Morning Session, Completes First Dosing in Phase IIa Trial for IBD Candidate Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Movement | INSILICO (03696) Surges Nearly 15% in Morning Session, Completes First Dosing in Phase IIa Trial for IBD Candidate Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-12 10:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>INSILICO (03696) rose nearly 15% in morning trading, hitting a high of HK$54, representing an increase of over 124% from its IPO price of HK$24.05. As of writing, the stock was up 14.89% at HK$54, with a turnover of HK$92.17 million.</p>\n<p>The company announced that it has completed the first subject dosing in a Phase IIa clinical trial named BETHESDA for its innovative PHD inhibitor, ISM5411. This novel candidate drug, which was developed with the assistance of the group's proprietary generative AI platform Pharma.AI, is a gut-restricted therapy intended for the treatment of Inflammatory Bowel Disease (IBD), and its generic name, Garutadustat, was recently officially approved by the United States Adopted Names (USAN) Council.</p>\n<p>Notably, on January 5, INSILICO announced that it had entered into a multi-year anti-cancer drug research collaboration with Servier. According to the announcement, the total potential value of the collaboration is $888 million. INSILICO is eligible to receive up to $32 million in an upfront payment and near-term research and development milestone payments. INSILICO will utilize its self-developed AI platform, Pharma.AI, to focus on challenging targets in the oncology field to identify and develop novel therapeutic agents. Servier will share the R&D costs and lead the subsequent clinical validation and commercialization process.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03696","symbol_name":"英矽智能","start_time":0,"source_url":"","article_id":"1170354154","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170354154","pubTimestamp":1768184218,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"INSILICO (03696) rose nearly 15% in morning trading, hitting a high of HK$54, representing an increase of over 124% from its IPO price of HK$24.05. As of writing, the stock was up 14.89% at HK$54,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03696":"英矽智能"},"translate_title":"港股动向|英矽智能(03696)早盘大涨近15%IBD候选药物IIa期试验完成首次给药","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03696":1},"content_text":"INSILICO (03696) rose nearly 15% in morning trading, hitting a high of HK$54, representing an increase of over 124% from its IPO price of HK$24.05. As of writing, the stock was up 14.89% at HK$54, with a turnover of HK$92.17 million.\nThe company announced that it has completed the first subject dosing in a Phase IIa clinical trial named BETHESDA for its innovative PHD inhibitor, ISM5411. This novel candidate drug, which was developed with the assistance of the group's proprietary generative AI platform Pharma.AI, is a gut-restricted therapy intended for the treatment of Inflammatory Bowel Disease (IBD), and its generic name, Garutadustat, was recently officially approved by the United States Adopted Names (USAN) Council.\nNotably, on January 5, INSILICO announced that it had entered into a multi-year anti-cancer drug research collaboration with Servier. According to the announcement, the total potential value of the collaboration is $888 million. INSILICO is eligible to receive up to $32 million in an upfront payment and near-term research and development milestone payments. INSILICO will utilize its self-developed AI platform, Pharma.AI, to focus on challenging targets in the oncology field to identify and develop novel therapeutic agents. Servier will share the R&D costs and lead the subsequent clinical validation and commercialization process.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1170354154","isCrawlerRequest":true}